首页> 外文期刊>Leukemia Research Reports >Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature
【24h】

Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature

机译:用伊布勒替尼的眼镜慢性淋巴细胞白血病成功治疗:病例报告和文学审查

获取原文
       

摘要

Clinically apparent neurological involvement by chronic lymphocytic leukemia (CLL), especially ocular manifestations, is rare. Standard diagnostic approaches for neurological or ocular CLL, including neuroimaging, have low yield and sensitivity and CSF flow cytometry remains the gold standard. Optical coherence tomography can yield helpful data and usually shows retinal pigment epithelial disruptions which may persist despite clinical improvement and resolution of MRI abnormalities. Our patient with ocular relapse with leukemic retinopathy and choroidal involvement was successfully treated with Ibrutinib monotherapy, lasting more than 2 years, highlighting the safety and efficacy of this agent regardless of site or type of relapse.
机译:临床上明显的慢性淋巴细胞白血病(CLL),特别是眼性表现的神经学中罕见。 包括神经影像动物的标准诊断方法,包括神经化学,具有低产量和敏感性,CSF流式细胞术仍然是金标准。 光学相干断层扫描可以产生有用的数据,并且通常显示视网膜颜料上皮破坏,尽管临床改善和解决MRI异常的分辨率可能会持续存在。 我们的患者用白血病单疗病和脉络膜培养的患者用伊布洛替尼单疗法成功地治疗,持续超过2年,突出了该试剂的安全性和功效,无论现场还是复发类型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号